
ESTRO 35 2016



Conclusion: This study shows an high consistency of small field dosimetry in the involved radiotherapy departments using this new generation silicon diode; consequently, the values reported may actually be used by other centers as indicative values, especially in the case of small fields when suitable detector are not commonly available. Moreover, these results confirm that the new RAZOR silicon diode can be used to assess dosimetric accuracy in small-field delivery. In general, the adopted methodology removes much of the ambiguity in reporting and interpreting small field dosimetric quantities and facilitates a clear dosimetric comparison across a population of linacs.

FP-1949

Developing a Radiotherapy Quality Assurance programme as part of the HIPPO trial (NCT02147028)

<u>D. Megias</u>¹, H. Yang¹, P. Sanghera², M. Phillips³, L. Senthil⁴, A. Jackson⁵, G. Whitfield^{6,7}

¹Mount Vernon Hospital, National Cancer Research Institute Radiotherapy Trials Quality Assurance Group, Middlesex, United Kinadom

²Queen Elizabeth Hospital, Hall Edwards Radiotherapy Research Group, Birmingham, United Kingdom

³Cancer Research UK, University College London Cancer Trials Centre, London, United Kingdom

⁴Queen Elizabeth Hospital, Neuroradiology, Birmingham, United Kingdom

⁵The University of Manchester, Wolfson Molecular Imaging Centre, Manchester, United Kingdom

⁶The University of Manchester- Manchester Academic Health Science Centre, Radiotherapy Related Research, Manchester, United Kingdom

The Christie NHS Foundation Trust, Clinical Oncology, Manchester, United Kingdom

Purpose or Objective: Outlining of target and OAR volumes is integral to the radiotherapy process but inherently subject to variability. The hippocampus is a small structure not commonly contoured by clinicians requiring considered anatomical interpretation in its delineation. HIPPO is a randomised phase II trial of Hippocampal Sparing (HS) versus Conventional Whole Brain Radiotherapy after surgical resection or radiosurgery in favourable prognosis patients with 1-4 brain metastases. We set out to inform the development of a dedicated HIPPO RTQA programme through evaluation of hippocampal contouring.

Material and Methods: Two clinical oncologists from different UK radiotherapy centres and a radiologist from each centre independently outlined the hippocampus on 2 different 1 mm slice thickness planning CT datasets after registration with the T1 weighted gadolinium enhanced MRI (3D volumetric MRI, axial acquisition, 1 mm slice thickness, no slice gap, 1 x 1 x 1 mm voxels) on their planning system. The datasets were re-registered by one of the centres. The four hippocampal contours for each case were anonymised and reviewed collectively and a gold standard contour defined. We compared each contour with its respective gold standard using the DICE coefficient and volume difference.

S925

Results:

| Table | 1 |
|-------|---|
|-------|---|

| Outliner | Case 1 | | Case 2 | |
|----------|-----------------------------------|---|-----------------------------------|--|
| | DICE similarity coefficient | Volume difference (cm ³) between outline and gold standard. | DICE similarity coefficient | Volume difference (cm ³) between outline and gold standard.) |
| 1 | 0.84 | 0.05 (-1%) | 0.79 | 1.9 (+26%) |
| 2 | 0.83 | 0.5 (+8%) | 0.86 | 1.01 (+15%) |
| 3 | 0.87 | 0.15 (+3%) | 0.75 | 0.41 (+7%) |
| 4 | 0.81 | 0.5 (+8%) | 0.81 | 0.75 (-13%) |

Conclusion: Reasonable concordance of the outlines in comparison to the gold standard was achieved in both cases. In case 1, all 4 outlines achieved a DICE coefficient greater than 0.80 and a hippocampal volume less than 0.5cm3 different to the gold standard. However, in case 2, despite DICE coefficients greater than 0.79 suggesting good spatial relationship between the clinicians' and the gold standard contour, greater variability was evident with a larger range in volume outlined. During collective review, some systematic differences were noted between the two participating centres' outlines, despite a high level of agreement on hippocampal boundaries during the review, highlighting CT-MRI co-registration as a potential source of variability between different centres and planning software. As a result of these findings, the pre-trial outlining benchmark case requires all centres to independently co-register the CT and MRI images and export the registration object as part of data submission. In order to comprehensively quality assure hippocampal outlining as part of the HIPPO RTQA programme, an on-trial component of the first two HS patient contours being reviewed prospectively before treatment is also undertaken. The implementation and quality assurance of less familiar outlining practice in the development of radiotherapy techniques requires careful consideration. This process has informed the development of a dedicated RTQA programme for the HIPPO trial highlighting the importance of aligning QA with clinical practice. HIPPO is funded by Cancer Research UK and The Brain Tumour Charity

EP-1950

Monte Carlo dose calculation of Viewray hybrid MRI-Co60 radiotherapy system: a repeatability study

<u>E. Placidi¹</u>, S. Teodoli¹, N. Dinapoli², L. Boldrini², G.C. Mattiucci², V. Valentini², A. Piermattei¹, L. Azario¹

¹Università Cattolica del Sacro Cuore -Policlinico A. Gemelli, Institute of Physics, Rome, Italy

²Università Cattolica del Sacro Cuore -Policlinico A. Gemelli, Radiation Oncology Department- Gemelli-ART, Rome, Italy

Purpose or Objective: The ViewRay MRI-Co60 hybrid system (MRIdian® [1,2]) is a novel technology that provides soft tissue imaging during radiotherapy thus allowing real adaptive radiotherapy possibilities and image guidance. The combination of Co60 with 0.35 Tesla MRI allows for MRguided intensity modulated radiation therapy (IMRT) step and shoot delivery with multiple beams (3 Co60 heads 120° apart). MRIdian dose calculation takes advantage of a full Monte Carlo-based algorithm. The aim of this work was to evaluate the repeatability of the dose calculation of MRIdian plans for rectal cancer treatments.

Material and Methods: Ten patients affected by locally advanced rectal cancer (cT3-cT4; cN0, cN+) were manually segmented on Eclipse TPS v11. MRIdian step and shoot IMRT plans (7 groups of 3 fields each) were calculated 5 times for each patient. The prescribed dose for PTV2 was 45 Gy and 55 Gy for PTV1 through simultaneous integrated boost. The PTV1 V95, the conformity index CI [3] and the Wu's homogeneity index HI were computed for each patient. The coefficient of variation (CV), defined as the ratio of the standard deviation to the mean, was calculated for each set to express the precision and repeatability of the Monte Carlo dose calculation. The estimated beam-on time was also recorded for each plan.